期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 13, 期 6, 页码 675-688出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728220902915567
关键词
cyclooxygenase-2; eicosanoids; non-small-cell lung cancer; prostaglandin E-2
资金
- NIH Vanderbilt Lung Cancer SPORE [CA90949]
Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E-2 (PGE(2)), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据